source
- FDA approves first generic radioligand therapy for neuroendocrine tumors as Sionna announces major layoffsThe U.S. Food and Drug Administration has cleared Bexlutry, the first generic version of Novartis’ Lutathera, marking the debut of a radioligand therapy that can be used for SSTR‑positive neuroendo…
- New antibody-drug conjugates show promise as potential standard for extensive-stage small cell lung cancer at WCLC 2026The World Conference on Lung Cancer showcased several late‑stage trial updates, with a focus on new therapies for small cell lung cancer, the more aggressive form of the disease. Antibody‑drug con…BioPharma Dive · 1mo agoPositive readoutPositive